(redirected from CXCR4)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to CXCR4: CCR5
See: notion
References in periodicals archive ?
Relations among expression of CXCR4, histological patterns, and metastatic potential in adenoid cystic carcinoma of the head and neck.
We also evaluated the involvement of SDF-1 and its chemokine receptor CXCR4 in homing of MSCs in injured lung compared with healthy organs.
Further, the expression of HIV-1 co-receptor molecules: CXCR4 and CCR5, and co-stimulatory molecules: CD40 and CD86 were analysed on the two DC subsets.
Unfortunately, HIV that uses the alterative receptor, CXCR4, becomes at least as common as CCR5-using HIV in people with more advanced HIV infection.
As an example, the sulfated polysaccharide fucoidan can act as an LSL and up-regulate the chemokine receptor CXCR4, a receptor for SDF-1, However, fucoidan also assists stem cell detachment within the marrow by binding to another adhesion receptor, CD1 lb, during stem cell mobilization.
Table 1: New drugs, target and phase of development Drug Target Phase Etravirine (ETV) NNRTI Approved Maraviroc (MVC) CCR5 Approved Raltegravir R ( AL) Integrase Approved Apricitabine NRTI I KP-1461 NRTI I UK-453,061 NNRTI I RDEA 427, 640, 806 NNRTI I IDX12989 NNRTI I PPL-100 PI I INCB9471 CXCR4 I INH-1001 Integrase I LED GF/p75 Integrase I Racivir (+/-FTC) NRTI I/II Bevirimat Maturation inhibitor I/II (PA-457) Amdoxovir NRTI I Elvucitabine NRTI I Rilpivirine NNRTI I BILR 355 BS NNRTI I SCH532706 CCR5 I PRO 140 CCR5 I Elvitegravir Integrase I TNX-335 Attachment inhibitor I (anti-CD4 Ab) Vicriviroc CCR5 II/III
We found that CXCR4 and CXCLI2 were downregulated and CXCR7 upregulated when normal VEGF expression is disrupted.
Two risks with this treatment approach are that the CCR5 may turn out to be necessary for some people for unknown reasons--or that when HIV is prevented from using CCR5, it might evolve within an individual patient to use CXCR4 instead.
Chemokine receptors CCR5 and CXCR4 are identified as the main co-receptors for HIV.
The review contains a discussion of the HIV-1 phenotypic variants defined by their use of the CCR5 or CXCR4 co-receptors.
The joint research and development program involves a chemical compound, CXCR4 Blocker, developed by Kureha.